Pharmacovigilance and biosimilars: considerations, needs and challenges

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.13, Iss.7, 2013-09, pp. : 1039-1047

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab biosimilars

By Vital Edward M

Expert Opinion on Biological Therapy, Vol. 13, Iss. 7, 2013-09 ,pp. : 1049-1062

Informa Healthcare

Access to resources Recommend Favorite

Are biosimilars really generics?

By Misra Anoop

Expert Opinion on Biological Therapy, Vol. 10, Iss. 4, 2010-04 ,pp. : 489-494

Informa Healthcare

Access to resources Recommend Favorite

Biosimilars: current status and future directions

By Roger Simon D

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1011-1018

Informa Healthcare

Access to resources Recommend Favorite

The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems

Current Biotechnology, Vol. 1, Iss. 4, 2012-11 ,pp. : 297-317

Bentham Science Publishers

Access to resources Recommend Favorite

The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems

By Wager Krista Jones Graham

Current Biotechnology, Vol. 1, Iss. 4, 2012-11 ,pp. : 297-317

Bentham Science Publishers

Access to resources Recommend Favorite